ImmunoGen Stock Climbs on Positive Ovarian Cancer Data

By Sam | March 25, 2018

ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost 12 percent in premarket trading.
Source: BioSpace

Posted in BioPharma